Europe Insulin Market

The insulin market in Europe is expected to grow from US$ 20,823.35 million in 2022 to US$ 38,279.77 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.

Increase in Incidence of Diabetes Bolsters Europe Insulin Market

Diabetes, a life-threatening chronic disease with no specialized cure, is mainly caused by the body’s incapacity to produce or effectively utilize the hormone insulin. This incapacity prevents the body from adequately regulating blood glucose levels. The incidence and prevalence of diabetes are rapidly increasing across Europe. Type 2 diabetes is the most prevalent form of diabetes and has grown alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to the International Diabetes Federation (IDF), ~537 million people were living with diabetes in 2021, and the number is expected to reach 643 million by 2030 and 783 million by 2045. Diabetes increases the risk of premature death of individuals by leading to complications in several body parts. Primary complications include heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Patients who have diabetes require frequent monitoring and external insulin administration. Thus, the rising prevalence of diabetes is driving the growth of the insulin market in Europe.

Market Overview

The Europe insulin market is subsegmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. The growth of the market in this region is expected to be the second largest after Germany. The prevalence of diabetes among all age groups in Europe is surging with the going commonness of obesity, unhealthy diet, and lacking physical inactivity. The prevalence of autoimmune type 1 Diabetes is rising in the region. Moreover, technologies such as insulin pumps, insulin pens, and continuous glucose monitoring devices are gaining significant acceptance in Europe. Europe has the world’s highest number of children with type 1 Diabetes. Type 1 diabetes is highly prevalent among children in the UK, Russia, and Germany. According to International Diabetes Federation (IDF), Germany has 7 million people diagnosed with diabetes, and it estimates that ~1.3 million people are expected to be living with undetected diabetes. According to the German Diabetes Centre (DDZ), diabetes would affect 12 million in the country by the end of 2040, and type 2 diabetes is anticipated to be a more prevalent type during the period.

 Europe Insulin Market Revenue and Forecast to 2028 (US$ Million)

Europe Insulin Strategic Insights

Strategic insights for the Europe Insulin provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Insulin Report Scope

Europe Insulin Regional Insights

The geographic scope of the Europe Insulin refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Europe Insulin Market Segmentation

The Europe insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.

• Based on long acting insulin, the Europe insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.
• Based on short acting insulin and traditional human insulin, the Europe insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.
• Based on concentrated insulin and combination insulin, the Europe insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022. 
• Based on biosimilar insulin, the Europe insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022. 
• Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2022.

Adocia; Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.